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ABSTRACT Very-long-chain fatty acids (VLCFAs)
have long been known to be degraded exclusively in
peroxisomes via -oxidation. A defect in peroxisomal
-oxidation results in elevated levels of VLCFAs and is
associated with the most frequent inherited disorder of
the central nervous system white matter, X-linked adre-
noleukodystrophy. Recently, we demonstrated that VL-
CFAs can also undergo -oxidation, which may provide
an alternative route for the breakdown of VLCFAs. The
-oxidation of VLCFA is initiated by CYP4F2 and
CYP4F3B, which produce -hydroxy-VLCFAs. In this
article, we characterized the enzymes involved in the
formation of very-long-chain dicarboxylic acids from
-hydroxy-VLCFAs. We demonstrate that very-long-
chain dicarboxylic acids are produced via two indepen-
dent pathways. The first is mediated by an as yet
unidentified, microsomal NAD-dependent alcohol de-
hydrogenase and fatty aldehyde dehydrogenase, which
is encoded by the ALDH3A2 gene and is deficient in
patients with Sjo¨gren-Larsson syndrome. The second
pathway involves the NADPH-dependent hydroxylation
of -hydroxy-VLCFAs by CYP4F2, CYP4F3B, or
CYP4F3A. Enzyme kinetic studies show that oxidation
of -hydroxy-VLCFAs occurs predominantly via the
NAD-dependent route. Overall, our data demonstrate
that in humans all enzymes are present for the com-
plete conversion of VLCFAs to their corresponding
very-long-chain dicarboxylic acids.—Sanders, R.-J., Of-
man, R., Dacremont, G., Wanders, R. J. A., Kemp, S.
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X-linked adrenoleukodystrophy (X-ALD; OMIM
300100) is the most common inherited peroxisomal
disorder with an incidence of 1 in 17,000 (1). It is a
progressive neurodegenerative disease that affects cere-
bral white matter, spinal cord, peripheral nerves, adre-
nal cortex, and testis (2). X-ALD is caused by mutations
in the ABCD1 gene, which encodes the adrenoleukodys-
trophy protein (ALDP), an ATP-binding cassette trans-
porter protein located in the peroxisomal membrane
(3). One of the primary peroxisomal functions is
detoxification of very-long-chain fatty acids (VLCFAs)
(22 carbons) by chain shortening via -oxidation (4).
Although the exact role of ALDP remains elusive, it has
been implicated in the transport of VLCFA into peroxi-
somes (5, 6). In patients with X-ALD, the defect in
ALDP results in decreased -oxidation of VLCFAs (7).
As a result, VLCFAs accumulate in all tissues and
plasma (8). In brain, ALDP is expressed in all glial cell
types, including astrocytes, microglial cells, and oligo-
dendrocytes (9). Myelinated tracts of oligodendrocytes
have a high lipid turnover. Therefore, incorporation of
VLCFAs, especially C26:0, in components of the multi-
lamellar myelin membrane might lead to destabiliza-
tion (10, 11). X-ALD is associated with increased levels
of VLCFAs. Hence, correction of VLCFA levels is the
primary objective in many therapeutic approaches,
including lovastatin treatment (12), dietary treatment
with Lorenzo’s oil (13), or induction of the expression
of the ALDP-related protein (14). The aim of other
interventions, such as gene replacement therapy (15)
and bone marrow transplantation (16), is to prevent
the incipient cerebral inflammatory demyelination by
replacing the malfunction gene.
Recently, we demonstrated that VLCFAs can also be
oxidized via another mechanism, i.e., -oxidation (17).
The first step in this pathway involves the hydroxylation
of the -methyl group of the VLCFA, generating a
-hydroxy-VLCFA. This reaction requires NADPH and
molecular oxygen as cofactors and is catalyzed by two
cytochrome P450 (CYP450) enzymes belonging to the
CYP4F subfamily, namely CYP4F2 and CYP4F3B (17).
Subsequently, the -hydroxy-VLCFA is oxidized further
into the corresponding dicarboxylic acid either via a
CYP450-mediated route or via an as yet unidentified
NAD-dependent pathway (17–21). Long-chain dicar-
boxylic acids are -oxidized in peroxisomes to shorter-
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chain dicarboxylic acids followed by excretion into the
urine (22). Studies with fibroblasts from patients with
X-ALD have demonstrated that -oxidation of long-
chain dicarboxylic acids is normal, in contrast to fibro-
blasts from patients with a peroxisomal biogenesis
disorder (22). These studies indicate that peroxisomes
are essential for the metabolism of dicarboxylic acids
and that this process does not require ALDP. Moreover,
patients with a peroxisomal biogenesis disorder excrete
considerable amounts of long-chain dicarboxylic acids
in urine (23). Stimulation of VLCFA -oxidation could
provide an interesting option to reduce VLCFA levels in
patients with X-ALD. It should be noted, however, that
as yet no data are available with respect to the -oxida-
tion capacity of peroxisomal very-long-chain dicarboxy-
lic acids.
The enzymes involved in the conversion of -hy-
droxy-VLCFA into their dicarboxylic acids have not
been identified. This information is of pivotal impor-
tance for further investigations to determine a thera-
peutic approach. In this article we have identified and
characterized the enzymes involved in the -oxidation
of VLCFAs in human microsomes.
MATERIALS AND METHODS
Chemicals
22-Hydroxydocosanoic acid (-hydroxy-C22:0) and hexaco-
sanedioic acid (C26:0-DCA) were purchased from Larodan
Fine Chemicals (Malmo¨, Sweden). A stock solution of 2.5 mM
was prepared in dimethyl sulfoxide. Disulfiram and 17-octa-
decynoic acid (17-ODYA) were from Sigma-Aldrich Corp. (St.
Louis, MO, USA). NAD and NADPH were from Roche
Applied Science (Almere, The Netherlands). Pooled human
liver S9, cytosol, and microsomes and recombinant human
CYP450-containing insect cell microsomes (Supersomes)
were from BD Biosciences/Gentest (Woburn, MA). The
CYP450 contents of Supersomes as provided by the manufac-
turer were CYP2E1 (588 pmol/mg), CYP2J2 (185 pmol/mg),
CYP3A4 (606 pmol/mg), CYP4A11 (120 pmol/mg), CYP4F2
(556 pmol/mg), CYP4F3A (33 pmol/mg), CYP4F3B (435
pmol/mg), and CYP4 F12 (213 pmol/mg). All other chemicals
used were of analytical grade.
Enzymatic -oxidation assays
The experimental conditions to study the -oxidation of
-hydroxy fatty acids were the same as those described
previously (17, 20) with minor modifications, as discussed
below.
NAD-dependent -oxidation assay
The reaction mixture contained glycine (100 mM); HEPES,
pH 9.7 (100 mM); protein (200 or 50 g/ml for -hydroxy-
C22:0 and -hydroxy-C26:0, respectively); -cyclodextrin
(1 mg/ml); and NAD (1 mM) in a total volume of 200 l.
NADPH-dependent -oxidation assay
The reaction mixture contained Tris buffer, pH 8.4 (100
mM), protein (50 g/ml), -cyclodextrin (1 mg/ml), and
NADPH (1 mM) in a total volume of 200 l. The reactions
were initiated by addition of the -hydroxy fatty acid at a final
concentration of 100 M and were allowed to proceed for 30
min at 37°C. After termination of the reactions by the
addition of 1 ml of hydrochloric acid (2 M), the reaction
products were extracted as described previously and analyzed
by electrospray ionization tandem mass spectrometry (24).
Tissue culture conditions
Fibroblasts were cultured in nutrient Ham’s F-10 medium
supplemented with 10% fetal calf serum, l-glutamine
(2 mM), penicillin (100 U/ml), and streptomycin (100 g/
ml) at 37°C under 5% CO2. Primary human fibroblast cell
lines were obtained from normal control subjects and pa-
tients with Sjo¨gren-Larsson syndrome (SLS). In each patient,
the diagnosis was established using clinical, biochemical, and
molecular methods, which included demonstration of defi-
cient fatty aldehyde dehydrogenase (FALDH) activity and the
identification of mutations in the ALDH3A2 gene (25). Cells
were harvested with trypsin and washed twice with PBS and
once with 0.9% NaCl. Cells were taken up in ice-cold PBS and
homogenized by sonication (two cycles of 10 s at 8 W) on ice,
and the protein concentration was determined using the
bicinchoninic acid method (28).
Subcellular fractionation studies
A liver biopsy sample was taken from a patient undergoing
abdominal surgery with informed consent from the patient to
use this material for scientific research. Approximately 1 g of
liver was washed and homogenized on ice, using a glass Potter
tube with a Teflon pestle, in 20 ml of ice-cold solution
containing 250 mM sucrose, 2.5 mM EDTA, and 5 mM
morpholinepropanesulfonic acid (MOPS) at pH 7.4. A post-
nuclear supernatant was obtained by centrifugation at 600 g
for 10 min at 4°C. An organellar pellet was prepared by
centrifugation at 12,000 g for 20 min at 4°C and used for
density gradient centrifugation as described (26). Marker
enzymes were measured to localize the different subcellular
compartments in the gradient, as described elsewhere (27).
Protein concentrations were determined using the bicincho-
ninic acid method (28).
RESULTS
Characterization of -hydroxy-VLCFA oxidation
To study the conversion of -hydroxy fatty acids into
their corresponding dicarboxylic acids, the assay was
optimized for -hydroxy-C22:0 using a postnuclear
supernatant prepared from human liver. The produc-
tion of C22:0-DCA was measured as a function of time,
substrate concentration, and pH either with NAD or
with NADPH as cofactor (Fig. 1). Formation of C22:0-
DCA in the presence of NAD was optimal at pH 9.7
(Fig. 1A), and at this pH product formation was linear
with time up to 60 min (Fig. 1B). The enzyme activity as
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a function of substrate concentration (Fig. 1C) was used
to calculate the kinetic constants Km and Vmax (Table 1).
With NADPH as cofactor, maximal activity was found
at pH 8.4 (Fig. 1D). At this pH, activity was linear up to
60 min (Fig. 1E). Again, the enzyme activity as a
function of substrate concentration (Fig. 1F) was used
to calculate the kinetic constants Km and Vmax (Table 1).
The optimal pH for the NAD- and NADPH-dependent
-oxidation routes were similar to the previously ob-
served pH optima in rat liver microsomes (20). These
optimal conditions were used to determine the enzyme
kinetic parameters for the two pathways with both
-hydroxy-C22:0 and -hydroxy-C26:0 using a post-
nuclear supernatant fraction as the source of enzyme
(Table 1). Both -hydroxy-fatty acids were substrates
for the NAD-dependent oxidation route as well as for
the NADPH-mediated pathway. Remarkably, the appar-
ent affinity (Km) as well as the catalytic efficiency
(Vmax/Km) were substantially higher with the -hy-
droxy-C26:0 as substrate compared with -hydroxy-
C22:0, independent of whether the NAD-dependent
or the NADPH-dependent pathway was studied.
Figure 1. Optimization of the -oxidation activity assay in human liver. For NAD-dependent -oxidation, protein samples were
incubated in a reaction mixture containing 100 mM glycine, 100 mM HEPES, 1 mM NAD, -cyclodextrin, and -hydroxy-
C22:0. Production of C22:0-DCA was measured as a function of pH (A), time (B), and -hydroxy-C22:0 concentration (C). For
NADPH-dependent -oxidation, reactions were performed in a reaction mixture containing 100 mM Tris  HCl buffer (pH 8.4)
and 1 mM NADPH. Formation of C22:0-DCA was determined as a function of pH (D), time (E), and -hydroxy-C22:0
concentration (F). The results are the means of three independent experiments; error bars represent the sd.
TABLE 1. NAD-dependent and NADPH-dependent -oxidation activity in different human liver subcellular fractions
-Hydroxy-C22:0 -Hydroxy-C26:0
Km
app (M) Vmax (pmol min
1 mg1) Vmax/Km Km
app (M) Vmax (pmol min
1 mg1) Vmax/Km
NAD-dependent
S9 11.6 341.9 29.4 2.7 138.4 51.3
Cytosol 10.8 44.7 4.1 8.0 33.5 4.2
Microsomes 11.8 628.5 53.3 1.2 219.0 182.5
NADPH-dependent
S9 21.5 147.5 6.9 3.0 66 22
Microsomes 20.8 568.6 27.3 3.8 256.5 69.9
Apparent Km (Km
app) and Vmax were calculated from Michaelis-Menten plots derived from two individual experiments in which
-hydroxy-C22:0 or -hydroxy-C26:0 was added at final concentrations ranging from 0.4 to 100 M.
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Subcellular localization of the NAD-dependent
-oxidation activity
To determine the subcellular localization of the con-
version of -hydroxy-VLCFAs into -carboxy-VLCFAs in
more detail, we measured the activity in fractions of a
human liver density gradient with NAD present. The
results depicted in Fig. 2 show that the activity profile
observed with both -hydroxy-C22:0 (Fig. 2G) and with
-hydroxy-C26:0 (Fig. 2H) closely mimics that of the
microsomal marker esterase (Fig. 2A). This finding
demonstrates that the NAD-dependent conversion of
-hydroxy-VLCFAs in human liver is associated with the
microsomal fraction.
Inhibition studies on NAD-dependent
dehydrogenase activity
As -oxidation of -hydroxy-VLCFAs is predominantly
associated with microsomes, we tested whether disul-
firam, which is a potent inhibitor of human microsomal
FALDH (28), also inhibits this activity, at least in the
presence of NAD. Figure 3 shows that the production
of the dicarboxylic acid of C22:0 decreased with in-
creasing disulfiram concentrations. Interestingly, the
decrease of C22:0-DCA was accompanied by an increase
of a peak at m/z value 353. On the basis of the
calculated m/z value this may represent the intermedi-
ate metabolite of -hydroxy-C22:0, i.e., the -aldehyde
of C22:0 (-oxo-C22:0). Unfortunately, -oxo-C22:0 is
not commercially available and is difficult to synthesize,
so that unequivocal evidence for the identity of -oxo-
C22:0 could not be obtained.
-Oxidation of -hydroxy-C22:0 in FALDH-deficient
fibroblasts
To provide conclusive evidence for a role of FALDH in
the conversion of -hydroxy-VLCFAs into the corre-
sponding dicarboxylic acids, fibroblasts from control
Figure 2. Subcellular localization of NAD-dependent -oxidation activity in a human liver Nycodenz density gradient. To
localize the different organelles in the gradient, the following marker enzymes were measured: esterase (microsomes) (A),
catalase (peroxisomes) (B), -hexosaminidase (lysosomes) (C), glutamate dehydrogenase (mitochondria) (D), phosphoglucoi-
somerase (cytosol) (E), protein (F), -hydroxy-C22:0 NAD-dependent activity (G), and -hydroxy-C26:0 NAD-dependent
activity (H). All enzyme activities are expressed as the percentage of total activity, and protein concentrations are expressed as
the percentage of total protein. The results are the mean of two independent experiments.
Figure 3. Effect of disulfiram on the NAD-dependent -ox-
idation activity of -hydroxy-C22:0. Protein samples were
preincubated for 10 min in the standard reaction mixture
with different concentrations of disulfiram. After preincuba-
tion, -hydroxy-C22:0 was added to a final concentration of
100 M. All data shown represent the means of two indepen-
dent experiments. , -oxo-C22:0; f, C22:0-DCA.
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subjects and patients with SLS were assayed for -oxi-
dation activity of -hydroxy-C22:0. The results depicted
in Fig. 4 show that the production of C22:0-DCA from
-hydroxy-C22:0 is markedly decreased in fibroblasts
from patients with SLS compared with control subjects.
Interestingly, the presumed -oxo-C22:0 intermediate
was found to accumulate to much higher levels in the
incubations with homogenates of fibroblasts from pa-
tients with SLS compared with homogenates from
control fibroblasts.
Identification of CYP450 -hydroxy fatty acid
hydroxylases
Because -hydroxy-VLCFAs can also be metabolized by
cytochrome P450 enzymes in the NADPH-driven -ox-
idation pathway, we investigated the effect of 17-ODYA
on enzyme activity (20). Previously, we demonstrated
that the NADPH and molecular oxygen-dependent
conversion of -hydroxy-C22:0 was inhibited markedly
by 17-ODYA, at least in rat liver microsomes (20).
17-ODYA is a specific inhibitor of CYP450 enzymes
belonging to the CYP4 family (29, 30). To determine
whether these enzymes are also involved in the -oxi-
dation of -hydroxy-VLCFAs in human, we studied the
effect of 17-ODYA on the production of C22:0-DCA and
C26:0-DCA in human liver microsomes. Figure 5 shows
that the formation of dicarboxylic acids either with
-hydroxy-C22:0 or with -hydroxy-C26:0 as substrate
was reduced strongly by 17-ODYA, with an IC50 of 0.8
M. Finally, microsomes from insect cells expressing
recombinant human CYP450 enzymes (Supersomes)
were used to investigate which human CYP450 enzymes
were reactive with -hydroxy-C22:0 and -hydroxy-
C26:0. The data in Fig. 6 show that four of the human
recombinant CYP450 enzymes that were tested,
CYP4F2, CYP4F3A, CYP4F3B, and CYP4A11, can use
-hydroxy-C22:0 as substrate. However, only CYP4F2
and CYP4F3B show activity toward -hydroxy-C26:0.
At optimal reaction conditions, the enzyme kinetic
parameters for the individually expressed CYP450 en-
zymes were determined using different substrates (Ta-
ble 2). CYP4F2 and CYP4F3B did show some enzymatic
activity with -hydroxy-C22:0 and -hydroxy-C26:0 as
substrates, although the apparent Km values were con-
siderably higher compared with the NAD-dependent
oxidation route in human liver postnuclear superna-
tant fractions (Table 1). In contrast, CYP4F3A displayed
a high affinity for -hydroxy-C22:0 (0.6 M), whereas
Figure 4. NAD-dependent -oxidation activity of -hydroxy-
C22:0 in human skin fibroblasts. The activity was measured in
fibroblast homogenates from control subjects (n	3) and
patients with SLS (n	3) as described. f, specific activity of
the production of -oxo-C22:0; , specific activity of the
production of C22:0-DCA. Error bars represent the sd.
Figure 5. Effect of 17-ODYA on the NADPH-dependent
CYP450-mediated -hydroxylation of -hydroxy-C22:0 (f)
and -hydroxy-C26:0 (). Protein samples were preincu-
bated for 10 min in the standard reaction mixture with
different concentrations of 17-ODYA. After preincubation,
the substrate was added to a final concentration of 100 M.
The results represent the mean of two independent experi-
ments.
Figure 6. Identification of cytochrome P450 enzymes involved
in the NADPH-dependent conversion of -hydroxy-VLCFAs
into dicarboxylic acids. , specific activity of human recom-
binant CYP450 enzymes with -hydroxy-C22:0; f, specific
activity of human recombinant CYP450 enzymes with -hy-
droxy-C26:0. Individual recombinant CYP450 proteins
(5 pmol) were incubated for 30 min in the standard CYP450
-oxidation reaction mixture at 37°C. All data shown repre-
sent the means of two independent experiments, which did
not vary by 10%.
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activity was below the limit of detection with longer
chain -hydroxy-VLCFAs such as -hydroxy-C26:0.
Overall, these data suggest that the oxidation of -hy-
droxy-fatty acids occurs predominantly via the NAD-
dependent route.
DISCUSSION
In this article we have studied the enzymatic conversion
of -hydroxy-VLCFAs into dicarboxylic acids in human
liver. Previously, we demonstrated that CYP4F2 and
CYP4F3B are involved in the NADPH-dependent -hy-
droxylation of VLCFAs in human liver (17). Although
the main product of these CYP450 enzymes is -hy-
droxy-VLCFAs, we also observed some -carboxy-VL-
CFAs being produced. Our studies using rat liver
microsomes revealed that the formation of -carboxy-
C22:0 from -hydroxy-C22:0 may follow two distinct
pathways, the first driven by NADPH and the second by
NAD (20). To elucidate whether these two pathways
exist in humans, enzyme assays were set up for both the
NAD-dependent and the NADPH-dependent path-
ways. Experiments with the individually expressed
CYP450 enzymes showed that CYP4F2, CYP4F3A,
CYP4F3B, and CYP4A11 displayed affinity toward -hy-
droxy-C22:0 whereas only CYP4F2 and CYP4F3B were
found to be active with -hydroxy-C26:0. Analysis of the
enzyme characteristics revealed that the NAD-depen-
dent pathway has the highest catalytic efficiency (Vmax/
Km) for both -hydroxy-C22:0 and -hydroxy-C26:0
compared with the NADPH-dependent route (Table
1). This finding suggests that the NAD-dependent
pathway is most likely the major route, at least in liver.
Subcellular localization studies in human liver indi-
cated that the NAD-dependent conversion of both
-hydroxy-C22:0 and -hydroxy-C26:0 is associated pre-
dominantly with the microsomes. The NAD-depen-
dent conversion of -hydroxy-VLCFAs into its -car-
boxy-VLCFAs needs the concerted action of an alcohol
dehydrogenase and an aldehyde dehydrogenase. At
present, 19 distinct aldehyde dehydrogenase genes
have been identified in the human genome (31). At
least three ALDHs have been localized to the endoplas-
mic reticulum and are encoded by the ALDH3B1,
ALDH3B2, and ALDH3A2 genes (32–34). ALDH3B1 is
expressed mainly in kidney and lung and ALDH3B2 is
expressed in the parotid glands. Microsomal FALDH
encoded by the ALDH3A2 gene is expressed predomi-
nantly in liver, heart, and muscle (35). FALDH cata-
lyzes the NAD-dependent oxidation of saturated and
unsaturated aliphatic aldehydes ranging from 6 to 24
carbons, with an optimal preference for substrates with
16 to 20 carbon atoms. In addition, FALDH interacts
with fatty alcohol dehydrogenase to form a fatty alco-
hol:NAD oxidoreductase enzyme complex that cata-
lyzes the overall conversion of fatty alcohols to fatty
acids (36). Both FALDH (35), and the NAD-depen-
dent conversion of -hydroxy-C22:0 are highly sensitive
toward disulfiram (Fig. 3), indicating that FALDH is
involved in this reaction. It has been reported previ-
ously that the human and rat microsomal aldehyde
dehydrogenases have different sensitivity toward disul-
firam (37, 38). This difference could explain the dis-
crepancy between the results described in this article
and our previous studies on the NAD-dependent
dehydrogenation of -hydroxy-C22:0 in rat liver micro-
somes (20). However, conclusive evidence was derived
from studies with fibroblasts from patients with SLS in
which FALDH is deficient owing to mutations in the
ALDH3A2 gene (25). These experiments showed that
FALDH indeed is involved in the conversion of -oxo-
C22:0 into the corresponding dicarboxylic acid. In
incubations with SLS fibroblast homogenates, the
amount of -carboxy-C22:0 was significantly reduced
compared with that in control fibroblasts. In addition,
SLS fibroblasts accumulated the presumed -oxo-C22:0
intermediate. It has been suggested that FALDH forms
a complex with a fatty alcohol dehydrogenase and that
the fatty alcohol dehydrogenase activity is the rate-
limiting step in the oxidation of fatty alcohols to fatty
acids (39). Our data suggest that there is some residual
alcohol dehydrogenase activity in the SLS fibroblasts
used.
To summarize, the human -oxidation system can
use VLCFAs for complete conversion into dicarboxylic
acids. The first rate-limiting step (Fig. 7A) is catalyzed
by cytochrome P450 enzymes belonging to the CYP4F
subfamily, i.e., CYP4F2 and CYP4F3B (17). Further
oxidation can occur via two distinct routes, including
the NAD-dependent oxidation route via an as yet
unidentified alcohol dehydrogenase and FALDH (Fig.
7B, C) or the NADPH-dependent route, which may
involve CYP4F2, CYP4F3A, CYP4F3B, and CYP4A11
TABLE 2. Enzymatic characterization of recombinant human P450 enzymes
-Hydroxy-C22:0 -Hydroxy-C26:0
Km
app (M) Vmax (pmol min
1 pmol P4501) Vmax/Km Km
app (M) Vmax (pmol min
1 mg1) Vmax/Km
CYP4F2 37.6 1.6 0.04 8.8 0.7 0.08
CYP4F3A 0.6 0.2 0.33 ND ND ND
CYP4F3B 13.1 0.3 0.02 5.2 0.8 0.15
Apparent Km (Km
app) and Vmax were calculated from Michaelis-Menten plots derived from two individual experiments in which
-hydroxy-C22:0 or -hydroxy-C26:0 was added at final concentrations ranging from 0.4 to 100 M. ND, not detectable.
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(Fig. 7D, E). Stimulation of VLCFA -oxidation by
increased expression of CYP4F2 and CYP4F3B would
affect not only the first reaction step of this pathway
(Fig. 7A) but also the subsequent reaction steps. Re-
cently, it has been shown that statins, i.e., lovastatin, are
able to induce the expression of the CYP4F2 gene via
sterol regulatory element-binding proteins (40). Al-
though there are conflicting data in the literature
considering statin treatment in patients with X-ALD,
early treatment with lovastatin may be beneficial for
patients with X-ALD through elevated expression of
CYP4F2 (14). We have established that the enzymatic
pathway necessary to convert VLCFAs to their corre-
sponding very-long-chain dicarboxylic acids is present
in humans. The aim of future experiments will be to
resolve whether induction of VLCFA -oxidation re-
sults in normalization of VLCFA levels in X-ALD.
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